135 related articles for article (PubMed ID: 35525376)
1. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103
Rischin D; Mehanna H; Young RJ; Bressel M; Dunn J; Corry J; Soni P; Fulton-Lieuw T; Iqbal G; Kenny L; Porceddu S; Wratten C; Robinson M; Solomon BJ;
Ann Oncol; 2022 Aug; 33(8):804-813. PubMed ID: 35525376
[TBL] [Abstract][Full Text] [Related]
2. Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.
Solomon B; Young RJ; Bressel M; Cernelc J; Savas P; Liu H; Urban D; Thai A; Cooper C; Fua T; Neeson P; Loi S; Porceddu SV; Rischin D
Ann Oncol; 2019 Oct; 30(10):1638-1646. PubMed ID: 31400196
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Rischin D; King M; Kenny L; Porceddu S; Wratten C; Macann A; Jackson JE; Bressel M; Herschtal A; Fisher R; Fua T; Lin C; Liu C; Hughes BGM; McGrath M; McDowell L; Corry J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):876-886. PubMed ID: 34098030
[TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
[TBL] [Abstract][Full Text] [Related]
6. Role of Human Papilloma Virus and Lifestyle Factors in Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma.
Nishikawa D; Hanai N; Ozawa T; Kitahara T; Hasegawa Y
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454395
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
8. An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer.
Corredor G; Toro P; Koyuncu C; Lu C; Buzzy C; Bera K; Fu P; Mehrad M; Ely KA; Mokhtari M; Yang K; Chute D; Adelstein DJ; Thompson LDR; Bishop JA; Faraji F; Thorstad W; Castro P; Sandulache V; Koyfman SA; Lewis JS; Madabhushi A
J Natl Cancer Inst; 2022 Apr; 114(4):609-617. PubMed ID: 34850048
[TBL] [Abstract][Full Text] [Related]
9. Disparities in survival outcomes among Black patients with HPV-associated oropharyngeal cancer.
Baliga S; Mitchell D; Yildiz VO; Gogineni E; Konieczkowski DJ; Grecula J; Blakaj DM; Liu X; Gamez ME
J Med Virol; 2023 Feb; 95(2):e28448. PubMed ID: 36583477
[TBL] [Abstract][Full Text] [Related]
10. The effect of human papillomavirus status on prognosis and local treatment strategies of T1-2N0 oropharyngeal squamous cell cancer.
Zhou P; Chen DL; Lian CL; Wu SG; Zhang SY
Front Public Health; 2022; 10():900294. PubMed ID: 35958856
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.
Vijayvargiya P; Trivedi S; Rupji M; Song H; Liu Y; Jiang R; Kaka AS; Chen GZ; Stokes W; Steuer C; Shin DM; Beitler JJ; Patel MR; Aiken A; Saba NF
Oncologist; 2022 Feb; 27(1):48-56. PubMed ID: 35305095
[TBL] [Abstract][Full Text] [Related]
12. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era.
Keane FK; Chen YH; Neville BA; Tishler RB; Schoenfeld JD; Catalano PJ; Margalit DN
Cancer; 2015 Aug; 121(15):2594-602. PubMed ID: 25873094
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas.
Carlander AF; Bendtsen SK; Rasmussen JH; Jakobsen KK; Garset-Zamani M; Grønhøj C; Friborg J; Hutcheson K; Johnson FM; Fuller CD; Moreno AC; Babarinde T; Gross ND; Myers JN; von Buchwald C
Eur J Cancer; 2024 May; 202():113983. PubMed ID: 38452723
[TBL] [Abstract][Full Text] [Related]
14. A real-world comparison of cisplatin vs cetuximab used concurrently with radiation in the treatment of locally advanced oropharyngeal carcinoma.
Fung AS; Afzal AR; Banerjee R; Debenham B; Hao D
Head Neck; 2021 Jan; 43(1):153-163. PubMed ID: 32949087
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
17. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
[TBL] [Abstract][Full Text] [Related]
18. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
19. Development and Assessment of a Novel Composite Pathologic Risk Stratification for Surgically Resected Human Papillomavirus-Associated Oropharyngeal Cancer.
Cramer JD; Dundar Y; Hotaling J; Raza SN; Lin HS
JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1105-1114. PubMed ID: 31042786
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 8
van Gysen K; Stevens M; Guo L; Jayamanne D; Veivers D; Wignall A; Pang L; Guminski A; Lee A; Hruby G; Macleod P; Taylor A; Eade T
BMC Cancer; 2019 Jul; 19(1):674. PubMed ID: 31288767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
